Loading...
Patients’ access to drugs with rebates in Switzerland – Empirical analysis and policy implications for drug pricing in Europe
BACKGROUND: Many European countries introduced (confidential) rebates in the past years. Authorities and manufacturers argue that this strategy allows reduction of spending on high-cost drugs, and quick access of innovative drugs. We evaluated these arguments using Switzerland as an example, one of...
Na minha lista:
| Udgivet i: | Lancet Reg Health Eur |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Elsevier
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7610666/ https://ncbi.nlm.nih.gov/pubmed/33899044 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lanepe.2021.100050 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|